1. Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis, and management recommendations for international practice. Pregnancy Hypertens 2022; 27:148–69.
2. Johnson S, Gordijn S, Damhuis S, et al. Diagnosis and monitoring of white coat hypertension in pregnancy: an ISSHP consensus Delphi procedure. Hypertension 2022; 79(5):993–1005.
3. Committee of experts of the Russian society of cardiology (RSC). Section on cardiovascular diseases in pregnant women. [National guidelines for diagnosis and treatment of cardiovascular diseases during pregnancy 2018]. New revision: July, 2018. Russ J Cardiol 2018; (7):156–200 [Russian].
4. Chulkov VS, Martynov AI, Kokorin VA. Hypertension in pregnancy: controversial issues of national and international guidelines. Russ J Cardiol 2020; 25(4S):4181.
5. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34):3165–241.
6. Magee LA, von Dadelszen P, Stones W, et al. The FIGO Textbook of Pregnancy Hypertension: an evidence-based guide to monitoring, prevention and management. London: The Global Library of Women’s Medicine; 2016:1–19.
7. Sipahioglu NT, Sipahioglu F. Closer look at white-coat hypertension. World J Methodol 2014; 26(3):144–50.
8. Roberts JM, Countouris M. White coat hypertension in pregnancy: the challenge of combining inconsistent data. Hypertension 2020; 76(1):35–7.
9. Ishikuro M, Obara T, Metoki H, et al. Blood pressure measured in the clinic and at home during pregnancy among nulliparous and multiparous women: the BOSHI study. Am J Hypertens 2013; 26(1):141–8.
10. Metoki H, Iwama N, Hamada H, et al. Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement. Hypertens Res 2022; 45(8):1298–309.
11. Ishikuro M, Obara T, Metoki H, et al. Parity as a factor affecting the white-coat effect in pregnant women: the BOSHI study. Hypertens Res 2015; 38:770–5.
12. Antza C, Cifkova R, Kotsis V. Hypertensive complications of pregnancy: A clinical overview. Metabolism 2018; 86:102–11.
13. Vestgaard M, Ásbjörnsdóttir B, Ringholm L, et al. White coat hypertension in early pregnancy in women with pre-existing diabetes: prevalence and pregnancy outcomes. Diabetologia 2019; 62(12):2188–99.
14. Helvaci MR, Kaya H, Duru M, et al. What is the relationship between white coat hypertension and dyslipidemia? Int Heart J 2008; 49:87–93.
15. Björklund K, Lind L, Vessby B, et al. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation 2002; 106(1):63–8.
16. Chulkov VS, Lenets EA, Chulkov VlS, et al. Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome. Arterial Hypertension 2020; 26(4):371–82.
17. Manios ED, Koroboki EA, Tsivgoulis GK, et al. Factors influencing white-coat effect. Am J Hypertens 2008; 21:153–8.
18. Streitel KL, Graham JE, Pickering TG, et al. Explaining gender differences in the white coat effect. Blood Press Monit 2011; 16:1–6.
19. Karter Y, Curgunlu A, Altinişik S, et al. Target organ damage and changes in arterial compliance in white coat hypertension. Is white coat innocent? Blood Press 2003; 12(5-6):307–13.
20. De la Sierra A, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. J Hypertens 2017; 35(12):2388–94.
21. 2Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension 2019; 73(5):e35–e66.
22. Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE Open Med 2019; 7:2050312119843700.
23. Rath W, Tsikouras P, Schlembach D. Ambulante und häusliche Blutdruckmessung bei hypertensiven Schwangeren. [Ambulatory and home blood pressure measurement in hypertensive pregnant women]. Z Geburtshilfe Neonatol 2020; 224(6):333–8 [German].
24. Sung SH, Cheng HM, Wang KL, et al. White coat hypertension is more risky than prehypertension: important role of arterial wave reflections. Hypertension 2013; 61(6):1346–53.
25. Benschop L, Duvekot JJ, Roeters van Lennep JE. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart 2019; 105(16):1273–8.
26. Ditisheim A, Wuerzner G, Ponte B, et al. Prevalence of hypertensive phenotypes after preeclampsia: a prospective cohort study. Hypertension 2018; 71(1):103–9.
27. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009; 27(8):1672–8.
28. Vestgaard M, Carstens Søholm J, Kjærhus Nørgaard S, et al. Home blood pressure in pregnancy - the upper reference limit. Blood Press Monit 2019; 24(4):191–8.
29. Brown MA, Mangos G, Davis G, et al. The natural history of white coat hypertension during pregnancy. BJOG 2005; 112(5):601–6.
30. Eguchi K, Ohmaru T, Ohkuchi A, et al. Ambulatory BP monitoring and clinic BP in predicting small-for-gestational-age infants during pregnancy. J Hum Hypertens 2016; 30:62–7.
31. Lima JMO, Lobo RU, Rodrigues DHDS, et al. What happened after birth to pregnant women undergoing ambulatory blood pressure monitoring (ABPM) for the diagnosis of hypertension? J Hum Hypertens 2020; 34(12):814–7.
32. Johnson S, Liu B, Kalafat E, et al. Maternal and perinatal outcomes of white coat hypertension during pregnancy: a systematic review and meta-analysis. Hypertension 2020; 76(1):157–66.
33. Ohkuchi A, Hirashima C, Arai R, et al. Temporary hypertension and white coat hypertension in the first trimester as risk factors for preeclampsia. Hypertens Res 2019; 42(12):2002–12.
34. Duffy JMN, Cairns AE, Richards-Doran D, et al. A core outcome set for pre-eclampsia research: an international consensus development study. BJOG 2020; 127(12):1516–26.
35. Duffy JMN, Cairns AE, Magee LA, et al. Standardizing definitions for the pre-eclampsia core outcome set: A consensus development study. Pregnancy Hypertension 2020; 21:208–17.
36. Sinitsin SP, Chulkov VS, Vereina NK. Hypertension in pregnant females with the risk of thrombogenicity: clinical forms, target organs damage, and hemostatic parameters. Arterial Hypertension 2009; 15(5):580–4.
37. Gencheva DG, Nikolov FP, Uchikova EH, et al. High-sensitivity CRP levels in women with gestational hypertension, preeclampsia and in normotensive pregnant women and its correlations. Folia Med (Plovdiv) 2021; 63(4):511–8.
38. Grover S, Brandt JS, Reddy UM, et al. Chronic hypertension, perinatal mortality and the impact of preterm delivery: a population-based study. BJOG 2022; 129:572–9.
39. Grassi G. White-coat hypertension: not so innocent. E-Journal of Cardiology Practice 2016; 14:26.
40. Chulkov VS, Nikolenko ES, Chulkov VlS. White-coat hypertension in pregnant women. South Russian Journal of Therapeutic Practice 2022; 3(4):25–31.
41. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409(6822):860–921.
42. Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res 2019; 47(D1):D155–D162.
43. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13(5):358–69.
44. Amaral LM, Sandrim VC, Kutcher ME, et al. Circulating total cell-free DNA levels are increased in hypertensive disorders of pregnancy and associated with prohypertensive factors and adverse clinical outcomes. Int J Mol Sci 2021; 22(2):564.
45. Li H, Zhang X, Wang F, et al. MicroRNA-21 lowers blood pressure in spontaneous hypertensive rats by upregulating mitochondrial translation. Circulation 2016; 134:734–51.
46. Jusic A, Devaux Y. Noncoding RNAs in hypertension. Hypertension 2019; 74:477–92.
47. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 2010; 3:251–5.
48. Cengiz M, Karatas OF, Koparir E, et al. Differential expression of hypertension-associated microRNAs in the plasma of patients with white coat hypertension. Medicine (Baltimore) 2015; 94:e693.
49. Kan C, Cao J, Hou J, et al. Correlation of miR-21 and BNP with pregnancy-induced hypertension complicated with heart failure and the diagnostic value. Exp Ther Med 2019; 17:3129–35.
50. Ishevskaya OP, Namitokov AM, Kosmacheva ED. Biomarkers of heart failure: current state of the problem. Innovative medicine of Kuban 2021; (4):67–72.
